American Assets Investment Management LLC Holds Position in Becton, Dickinson and Company (BDX)

American Assets Investment Management LLC held its position in Becton, Dickinson and Company (NYSE:BDX) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,000 shares of the medical instruments supplier’s stock at the end of the first quarter. American Assets Investment Management LLC’s holdings in Becton, Dickinson and Company were worth $917,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. North Star Investment Management Corp. raised its stake in Becton, Dickinson and Company by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after buying an additional 18 shares during the last quarter. Crestwood Advisors Group LLC bought a new stake in Becton, Dickinson and Company during the first quarter valued at $101,000. Financial Architects Inc raised its stake in Becton, Dickinson and Company by 62.7% in the first quarter. Financial Architects Inc now owns 677 shares of the medical instruments supplier’s stock valued at $124,000 after buying an additional 261 shares during the last quarter. Glassman Wealth Services raised its stake in Becton, Dickinson and Company by 0.7% in the fourth quarter. Glassman Wealth Services now owns 854 shares of the medical instruments supplier’s stock valued at $141,000 after buying an additional 6 shares during the last quarter. Finally, Cribstone Capital Management LLC raised its stake in Becton, Dickinson and Company by 320.2% in the first quarter. Cribstone Capital Management LLC now owns 874 shares of the medical instruments supplier’s stock valued at $161,000 after buying an additional 666 shares during the last quarter. Institutional investors and hedge funds own 75.47% of the company’s stock.

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Becton, Dickinson and Company (BDX) opened at 191.29 on Friday. The stock has a market capitalization of $40.80 billion, a PE ratio of 31.77 and a beta of 1.04. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $194.11. The company’s 50-day moving average price is $187.33 and its 200 day moving average price is $179.43.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Tuesday, May 2nd. The medical instruments supplier reported $2.30 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.23 by $0.07. Becton, Dickinson and Company had a return on equity of 25.37% and a net margin of 10.67%. The business had revenue of $2.97 billion for the quarter, compared to analyst estimates of $2.92 billion. During the same period in the previous year, the company earned $2.18 earnings per share. The company’s revenue for the quarter was down 3.2% compared to the same quarter last year. On average, analysts forecast that Becton, Dickinson and Company will post $9.45 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, June 30th. Investors of record on Friday, June 9th will be paid a $0.73 dividend. The ex-dividend date is Wednesday, June 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.53%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 48.26%.

ILLEGAL ACTIVITY NOTICE: “American Assets Investment Management LLC Holds Position in Becton, Dickinson and Company (BDX)” was published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://transcriptdaily.com/2017/06/17/american-assets-investment-management-llc-has-917000-stake-in-becton-dickinson-and-co-bdx-updated.html.

A number of research firms have weighed in on BDX. Royal Bank Of Canada reiterated a “hold” rating and issued a $177.00 target price on shares of Becton, Dickinson and Company in a research note on Thursday, April 13th. Jefferies Group LLC reissued a “buy” rating and set a $200.00 price target on shares of Becton, Dickinson and Company in a research report on Wednesday, March 29th. Evercore ISI raised Becton, Dickinson and Company from an “in-line” rating to an “outperform” rating and increased their price target for the stock from $186.00 to $200.00 in a research report on Monday, April 24th. Finally, Zacks Investment Research raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating and set a $206.00 price objective on the stock in a research report on Tuesday, April 11th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $186.09.

In related news, VP Jeffrey S. Sherman sold 28,765 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $185.98, for a total value of $5,349,714.70. Following the completion of the transaction, the vice president now directly owns 70,821 shares in the company, valued at $13,171,289.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply